CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RayzeBio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RayzeBio Inc
5505 Morehouse Drive, Suite 300
Phone: (619) 937-2754p:619 937-2754 SAN DIEGO, CA  92121  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 2/26/2024.
This company ceased filing statements with the SEC on 3/7/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The Company is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The Company's drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The Company is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard H.Heyman 66 12/1/2022 12/1/2022
President, Chief Executive Officer, Director KenSong 48 7/1/2020 1/1/2019
Chief Financial Officer ArvindKush 40 4/1/2021 4/1/2021
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 88 (As of 6/30/2023)
Outstanding Shares: 61,034,144 (As of 12/25/2023)
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024